Table 2.
Symbol | Treatment 1 | SEM | p-Value | |||
---|---|---|---|---|---|---|
Control | TTO | LPS | TTO + LPS | |||
TLR-2 | 1.00 b | 0.70 c | 3.15 a | 1.84 b | 0.30 | <0.001 |
TLR-4 | 1.00 b | 1.09 a,b | 0.92 b | 1.44 a | 0.07 | 0.018 |
CCL5 | 1.02 | 0.94 | 1.78 | 1.55 | 0.15 | 0.105 |
MYD88 | 1.00 | 0.78 | 0.83 | 1.24 | 0.80 | 0.178 |
TOLLIP | 1.01 | 0.64 | 0.84 | 0.98 | 0.06 | 0.049 |
IRF3 | 1.00 b | 1.19 b | 1.15 b | 1.45 a | 0.05 | 0.001 |
NF-κB | 1.01 b | 0.73 b | 1.82 a | 1.67 a | 0.14 | <0.001 |
IFIT3 | 1.01 a | 0.62 b | 1.20 a | 0.43 b | 0.10 | 0.002 |
CXCL6 | 1.00 c | 0.76 c | 12.31 a | 4.28 b | 1.44 | <0.001 |
a,b,c, Means in the same row with different superscripts differ significantly for treatment effect (p < 0.05). 1 GRECs were cultured in DMEM/F12 medium, DMEM/F12 medium supplemented with 0.05% TTO, DMEM/F12 medium supplemented with 1 µg/mL lipopolysaccharide and DMEM/F12 medium supplemented with 1 µg/mL lipopolysaccharide and 0.05% TTO for 24 h, respectively.